Heteroaromatic compounds and their use as dopamine D1 ligands

US9822097B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Michael Aaron Brodney · East Lyme, US
• Jennifer Elizabeth Davoren · Cambridge, US
• Amy Beth Dounay · Colorado Springs, US
• Ivan Viktorovich Efremov · Sharon, US
• David Lawrence Firman Gray · Groton, US
• Michael Eric Green · Boston, US
• Jaclyn Louise Henderson · Cambridge, US
• Chewah Lee · Wallingford, US
• Scot Richard Mente · Arlington, US
• Steven Victor O'Neil · East Lyme, US
• Bruce N. Rogers · Belmont, US
• Lei Zhang · Beijing, CN

Key dates

• Filing date: Nov 11, 2016
• Grant date: Nov 21, 2017
• Expiry date: Nov 11, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.